Is MiMedx Stock a Good Investment?
MiMedx Investment Advice | MDXG |
- Examine MiMedx's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MiMedx's leadership team and their track record. Good management can help MiMedx navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MiMedx's business and its evolving consumer preferences.
- Compare MiMedx's performance and market position to its competitors. Analyze how MiMedx is positioned in terms of product offerings, innovation, and market share.
- Check if MiMedx pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MiMedx's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MiMedx Group stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MiMedx Group is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine MiMedx Stock
Researching MiMedx's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 68.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.97. MiMedx Group had not issued any dividends in recent years. The entity had 3235:10000 split on the 2nd of April 2008.
To determine if MiMedx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MiMedx's research are outlined below:
| MiMedx Group appears to be risky and price may revert if volatility continues | |
| MiMedx Group is unlikely to experience financial distress in the next 2 years | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Maersk-moller Kimberly of 125581 shares of MiMedx subject to Rule 16b-3 |
MiMedx Quarterly Good Will |
|
MiMedx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MiMedx Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MiMedx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MiMedx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MiMedx's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2023-10-30 | 2023-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2022-11-02 | 2022-09-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2022-05-03 | 2022-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2017-02-23 | 2016-12-31 | 0.08 | 0.07 | -0.01 | 12 | ||
2016-04-25 | 2016-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2015-04-27 | 2015-03-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2014-10-30 | 2014-09-30 | 0.02 | 0.03 | 0.01 | 50 |
Know MiMedx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MiMedx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MiMedx Group backward and forwards among themselves. MiMedx's institutional investor refers to the entity that pools money to purchase MiMedx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Royal Bank Of Canada | 2024-09-30 | 1.1 M | Harbor Capital Advisors Inc | 2024-09-30 | 1 M | Royce & Associates, Lp | 2024-09-30 | 972.9 K | Federated Hermes Inc | 2024-09-30 | 906.8 K | Qube Research & Technologies | 2024-09-30 | 894.7 K | Richmond Brothers Inc | 2024-09-30 | 782.7 K | Essex Woodlands Health Ventures | 2024-09-30 | 28.2 M | Blackrock Inc | 2024-06-30 | 9.3 M |
MiMedx's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.39 B.Market Cap |
|
MiMedx's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.31 | 0.33 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.28 | 0.30 | |
| Return On Equity | 0.47 | 0.45 |
Determining MiMedx's profitability involves analyzing its financial statements and using various financial metrics to determine if MiMedx is a good buy. For example, gross profit margin measures MiMedx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MiMedx's profitability and make more informed investment decisions.
Evaluate MiMedx's management efficiency
MiMedx Group has return on total asset (ROA) of 0.1838 % which means that it generated a profit of $0.1838 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6247 %, meaning that it created $0.6247 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Total Current Assets are most likely to increase significantly in the upcoming years. The MiMedx's current Intangible Assets is estimated to increase to about 9.5 M, while Other Current Assets are projected to decrease to roughly 4.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.23 | 1.29 | |
| Tangible Book Value Per Share | 1.01 | 1.06 | |
| Enterprise Value Over EBITDA | 24.38 | 25.60 | |
| Price Book Value Ratio | 7.16 | 6.80 | |
| Enterprise Value Multiple | 24.38 | 25.60 | |
| Price Fair Value | 7.16 | 6.80 | |
| Enterprise Value | 987.8 M | 1 B |
The management strategies employed by MiMedx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.939 |
Basic technical analysis of MiMedx Stock
As of the 17th of December 2024, MiMedx secures the mean deviation of 2.1, and Risk Adjusted Performance of 0.1265. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MiMedx Group, as well as the relationship between them. Please verify MiMedx Group standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if MiMedx Group is priced some-what accurately, providing market reflects its recent price of 9.54 per share. Given that MiMedx Group has jensen alpha of 0.6516, we recommend you to check MiMedx's last-minute market performance to make sure the company can sustain itself at a future point.MiMedx's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MiMedx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MiMedx's Outstanding Corporate Bonds
MiMedx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MiMedx Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MiMedx bonds can be classified according to their maturity, which is the date when MiMedx Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand MiMedx's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MiMedx's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1265 | |||
| Market Risk Adjusted Performance | 2.49 | |||
| Mean Deviation | 2.1 | |||
| Semi Deviation | 1.3 | |||
| Downside Deviation | 1.84 | |||
| Coefficient Of Variation | 610.62 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.34 | |||
| Information Ratio | 0.1433 | |||
| Jensen Alpha | 0.6516 | |||
| Total Risk Alpha | 0.2376 | |||
| Sortino Ratio | 0.3247 | |||
| Treynor Ratio | 2.48 | |||
| Maximum Drawdown | 26.54 | |||
| Value At Risk | (2.97) | |||
| Potential Upside | 3.19 | |||
| Downside Variance | 3.38 | |||
| Semi Variance | 1.69 | |||
| Expected Short fall | (2.63) | |||
| Skewness | 4.22 | |||
| Kurtosis | 20.78 |
| Risk Adjusted Performance | 0.1265 | |||
| Market Risk Adjusted Performance | 2.49 | |||
| Mean Deviation | 2.1 | |||
| Semi Deviation | 1.3 | |||
| Downside Deviation | 1.84 | |||
| Coefficient Of Variation | 610.62 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.34 | |||
| Information Ratio | 0.1433 | |||
| Jensen Alpha | 0.6516 | |||
| Total Risk Alpha | 0.2376 | |||
| Sortino Ratio | 0.3247 | |||
| Treynor Ratio | 2.48 | |||
| Maximum Drawdown | 26.54 | |||
| Value At Risk | (2.97) | |||
| Potential Upside | 3.19 | |||
| Downside Variance | 3.38 | |||
| Semi Variance | 1.69 | |||
| Expected Short fall | (2.63) | |||
| Skewness | 4.22 | |||
| Kurtosis | 20.78 |
Consider MiMedx's intraday indicators
MiMedx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MiMedx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MiMedx Corporate Filings
8K | 16th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
MiMedx Stock media impact
Far too much social signal, news, headlines, and media speculation about MiMedx that are available to investors today. That information is available publicly through MiMedx media outlets and privately through word of mouth or via MiMedx internal channels. However, regardless of the origin, that massive amount of MiMedx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MiMedx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MiMedx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MiMedx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MiMedx alpha.
MiMedx Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MiMedx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MiMedx Corporate Management
| Matthew Notarianni | Head Relations | Profile | |
| Todd Newton | Interim Director | Profile | |
| William Phelan | VP Officer | Profile | |
| Kim Moller | Chief Officer | Profile | |
| William IV | General Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.59 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between MiMedx's value and its price, as these two are different measures arrived at by various means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.